The IMWG report on the newly developed revised version of the International Staging System (R-ISS) which incorporates chromosomal abnormalities to develop a more powerful staging system for stratifying myeloma patients.
This paper, produced by an expert panel of the International Myeloma Working Group (IMWG), provides consensus updates on the disease definition of myeloma which now include validated biomarkers in addition to the presence of the traditional ‘CRAB’ criteria.
This paper, written by an expert panel on behalf of the International Myeloma Working Group, addresses the need for new uniform response criteria for myeloma patients.
This article, produced by the International Myeloma Working Group, reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of transplantation-eligible myeloma patients.
This paper provides an update to the first guideline published in 2005 by the International Myeloma Working Group on the management of myeloma patients who are ineligible for high-dose therapy and autologous stem cell transplantation. It includes recommendations on the diagnosis and treatment of these patients together with the management of side-effects of treatment.
This paper, written by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the available evidence and provides recommendations for the management of myeloma-related bone disease. It also includes expert consensus to propose additional recommendations where there were insufficient published data.
Maintaining results of successful induction treatment is an important goal in myeloma and the use of maintenance treatment to achieve this has been investigated for a number of years. Here, members of the International Myeloma Working Group review the relevant data and draw a consensus on maintenance treatment in myeloma.
In this article, members of the International Myeloma Working Group review the available data and provide new recommendations for the management of MGUS and smouldering myeloma patients.
In this paper, members of the International Myeloma Working Group summarise the data from prospective and retrospective studies of allogeneic stem cell transplantation in myeloma and provide recommendations for new safer approaches whilst preserving the graft versus myeloma effect.
This paper, produced by the International Myeloma Working Group, summarises the available evidence and provides recommendations for a prophylaxis strategy according to a risk assessment model, to reduce the risk of a venous thromboembolic event in myeloma patients.